Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update June 10, 2025 Legal Notices The information in this slide deck is current as of June 10, 2025, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and ...

For purposes of this notice, the "presentation" that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. ("Immunome") or any person on its behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. References to "we," "our," and "us" refers to Immunome and its subsidiaries. This presentation shall not cons ...

Accessibility StatementSkip Navigation ADC Platforms Keynote speech R&D Strategy "Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies," said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. "We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innov ...

BeiGene (BGNE) Update / Briefing June 26, 2025 08:30 AM ET Speaker0 Hello, everyone. Welcome to b one medicine's twenty twenty five investor research and development day. My name is Liza Heaps. I'm senior director of investor relations at b one. We are very excited to host our investor event today, both in person in New York City and online for our global attendees. Thank you all very much for joining us. This is truly an exciting time at b one, and we are thrilled to walk you through recent progress to dat ...

5 June 2025 China Pharma and Biotech China Pharma & Biotech: ASCO 2025 Part 3 - positive updates from IBI363, ZL-1310, and SHR-1826; review of highlights Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com Extensive stage small cell lung cancer (ES-SCLC): Zai Lab provided further detail on ZL-1310 (DLL3 ADC) in 2L+ ES-SCLC at the oral session. In addition to the 68% ORR of the dose escalation group (n=28), there were notable results in t ...

Core Insights - Astellas Pharma has entered into an exclusive license agreement with Evopoint Biosciences for the development and commercialization of XNW27011, a novel investigational antibody-drug conjugate targeting CLDN18.2, with worldwide rights excluding certain regions in China [1][3][6] Group 1: Agreement Details - The agreement grants Astellas exclusive worldwide rights (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop and commercialize XNW27011 [1] - Evopoint will receive a $130 million upfront payment and is eligible for up to $70 million in near-term payments, with additional milestone payments totaling up to $1.34 billion, plus royalties on net sales if approved [1][4] Group 2: Clinical Development - XNW27011 is currently being evaluated in a Phase 1/2 study in China for patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer, and pancreatic cancer [2][3] - The drug utilizes a proprietary topoisomerase I inhibitor payload and linker technology, which has shown clinical success in other approved cancer therapies [2] Group 3: Strategic Importance - Astellas has significant expertise in developing therapies targeting CLDN18.2, including VYLOYTM, the first CLDN18.2-targeted therapy approved globally [3] - The addition of XNW27011 is expected to address unmet patient needs and expand Astellas' oncology pipeline, which includes various CLDN-targeting therapies and ADCs directed at other targets [3][5]

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented June 2, 2025, 1:30 pm-4:30 pm CT BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together ...

Core Insights - BioNTech will present clinical trial data from its oncology portfolio at the ASCO Annual Meeting, showcasing progress in mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies [1][4] Group 1: Clinical Trial Highlights - The company is advancing over 20 active Phase 2 and 3 clinical trials, focusing on investigational mRNA cancer immunotherapies and the next-generation immunomodulator BNT327 [4] - BNT327, an investigational anti-PD-L1xVEGF-A antibody, will have three presentations detailing data from ongoing clinical trials, including a Phase 2 trial for malignant mesothelioma and Phase 3 trials for small cell lung cancer [5][8] - Data on BNT324/DB-1311, a B7H3-targeted ADC candidate, will be presented, indicating early clinical activity in heavily pre-treated castration-resistant prostate cancer [5][8] Group 2: Future Directions - BioNTech aims to become a diversified multi-product oncology company, with multiple data readouts expected in 2025 and 2026 [4] - The company emphasizes the potential of its assets to improve patient outcomes through innovative therapeutic modalities [2][4] - The presentations at ASCO are part of BioNTech's strategy to shape the future of cancer medicine through complementary mechanisms and innovative molecules [2]

Core Insights - ALX Oncology is advancing ALX2004, a potential best- and first-in-class antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumors, designed to maximize therapeutic efficacy while minimizing toxicity [1][2] - The U.S. FDA has cleared the IND application for ALX2004, with clinical studies set to begin in mid-2025 and initial safety data expected in the first half of 2026 [1][6] - The company plans to initiate trials for its lead therapy, evorpacept, in breast and colorectal cancers around the same time, with significant milestones anticipated in 2026 [1] ALX2004 Development Overview - ALX2004 is developed using a proprietary linker-payload platform, featuring an affinity-tuned EGFR antibody and a stable linker-Top1i payload, aimed at enhancing anti-tumor activity and reducing toxicity [3][4] - Preclinical data indicates that ALX2004 has superior stability and a favorable safety profile compared to other ADCs, showing dose-dependent activity across various tumors and EGFR expression levels [5] Clinical Trial Plans - The Phase 1 clinical trial for ALX2004 will target EGFR-expressing solid tumors, including non-small cell lung cancer and colorectal cancer, focusing on patients with relapsed or refractory cancers [6] - The trial is expected to begin in mid-2025, with initial safety data anticipated in the first half of 2026 [1][6]

Core Insights - CytomX Therapeutics announced positive interim clinical results for CX-2051, an EpCAM-directed antibody-drug conjugate (ADC) for advanced colorectal cancer (CRC), highlighting its strategic importance for the company [3][7] - The company has initiated dose expansions for CX-2051 at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, with a Phase 2 study planned for the first half of 2026 [7][3] - Financial results for Q1 2025 show total revenue of $50.9 million, an increase from $41.5 million in Q1 2024, driven by collaborations with Bristol Myers Squibb and Amgen [9][10] Pipeline Program Updates - CX-2051 is currently in a Phase 1 dose escalation study, with an update on data from at least 70 patients expected by Q1 2026 [7] - CX-801, a PROBODY interferon alpha-2b, is also in development, with initial Phase 1a translational data expected in the second half of 2025 [7][5] - The company is focusing on combination therapy with CX-801 and KEYTRUDA, aiming to initiate this in 2025 [7] Financial Overview - As of March 31, 2025, the company reported cash, cash equivalents, and investments totaling $79.9 million, down from $100.6 million at the end of 2024 [8] - Total operating expenses for Q1 2025 were $28.3 million, a decrease from $29.8 million in Q1 2024, with R&D expenses at $18.9 million, down from $22.1 million [10][11] - The net income for Q1 2025 was $23.5 million, compared to $13.8 million in Q1 2024, reflecting improved operational efficiency [18]